When and how should hydroxyzine (Atarax) be used as a short‑term adjunct or alternative to an SSRI for depression or anxiety?

Hydroxyzine (Atarax) as a Short-Term Adjunct for Anxiety

Hydroxyzine should be reserved as a short-term adjunct (not exceeding 4 months) for acute anxiety symptoms in patients already on SSRIs, or as a brief bridge therapy while titrating antidepressants, but it is not recommended as monotherapy or long-term treatment for depression or generalized anxiety disorder. 1

When to Consider Hydroxyzine

FDA-Approved Indications

• Symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states where anxiety is manifested 1
• The FDA label explicitly states that effectiveness for long-term use (more than 4 months) has not been assessed by systematic clinical studies 1
• Physicians must periodically reassess the usefulness of the drug for each individual patient 1

Clinical Scenarios Where Hydroxyzine May Be Appropriate

• Acute pre- or post-meal anxiety in patients with eating disorders already receiving SSRIs, where hydroxyzine contributed to similar anxiety reductions in a more challenging subset of patients 2
• Short-term insomnia in adults for whom previous therapy was ineffective, not tolerated, or contraindicated, though evidence shows mixed efficacy 3
• Premedication and post-anesthesia sedation, where hydroxyzine may potentiate meperidine and barbiturates 1

Why SSRIs Remain First-Line

Superior Evidence Base

• Antidepressants (SSRIs/SNRIs) are significantly more effective than placebo for generalized anxiety disorder, with a risk ratio of 1.41 (95% CI 1.29 to 1.55) and a number needed to treat of 7 4
• High-certainty evidence supports SSRIs as first-line treatment for both depression and anxiety disorders 5, 4
• For children and adolescents with anxiety disorders, combination treatment (CBT plus SSRI) is superior to monotherapy, with moderate strength of evidence 5

Hydroxyzine's Limited Evidence

• A Cochrane review found hydroxyzine more effective than placebo for GAD (OR 0.30,95% CI 0.15 to 0.58), but concluded it cannot be recommended as a reliable first-line treatment due to high risk of bias in included studies, small sample sizes, and limited number of trials 6
• Among non-antidepressant treatments, pregabalin and quetiapine have more robust evidence than hydroxyzine for GAD 7

How to Use Hydroxyzine as an Adjunct

Dosing and Administration

• FDA-approved doses: 25 mg, 50 mg, or 100 mg at bedtime for sleep 3
• For anxiety: Dosing should be individualized, but studies used 10 mg/kg intraperitoneally in animal models 8
• Start at the low end of the dosing range in elderly patients due to greater frequency of decreased hepatic, renal, or cardiac function 1

Critical Safety Warnings

• Potentiates CNS depressants: When used with narcotics, non-narcotic analgesics, or barbiturates, reduce the dosage of these agents 1
• Drowsiness risk: Patients must be warned against driving or operating dangerous machinery 1
• Avoid alcohol: The effect of alcohol may be increased 1
• Elderly patients: Sedating drugs may cause confusion and oversedation; start on low doses and observe closely 1

Monitoring Requirements

• Reassess periodically (at least every 4 months) whether continued use is justified 1
• Monitor for excessive sedation, particularly in elderly patients 1
• Watch for dry mouth, the most common adverse effect 3

Common Pitfalls to Avoid

Do Not Use Hydroxyzine When:

• Monotherapy for depression or GAD is needed: SSRIs/SNRIs have superior evidence and should be first-line 5, 9, 4
• Long-term treatment is required: No evidence supports use beyond 4 months 1
• Combining with multiple CNS depressants: Risk of excessive sedation and respiratory depression 1
• Patient requires alertness: Drowsiness is common and may impair function 1

Preferred Alternatives

• For treatment-resistant anxiety on SSRIs: Consider switching to another SSRI (sertraline, escitalopram) or adding CBT rather than adding hydroxyzine 10
• For insomnia with depression/anxiety: Sedating antidepressants (trazodone, mirtazapine) are preferred over antihistamines like hydroxyzine 11
• For chronic GAD: Pregabalin has more robust evidence than hydroxyzine 7

Combination with SSRIs: Limited Benefit

• A study combining duloxetine with hydroxyzine showed no additional benefit over monotherapy in animal models of anxiety 8
• The combination showed similar results to respective monotherapies in both in vivo models and brain monoamine estimations 8
• This suggests that adding hydroxyzine to an SSRI may not enhance efficacy beyond what the SSRI provides alone

Bottom Line Algorithm

1. Start with an SSRI (sertraline, escitalopram, or fluoxetine) for depression or GAD 5, 9, 12
2. Add CBT whenever possible for superior outcomes 5
3. If acute anxiety persists after 6-8 weeks of adequate SSRI dosing, consider:
   • Switching to another SSRI or SNRI 10
   • Augmenting with pregabalin (stronger evidence) 7
   • Using hydroxyzine only for short-term relief (< 4 months) of breakthrough anxiety 1, 6
4. Reassess monthly if hydroxyzine is used, with a plan to taper once acute symptoms resolve 1
5. Never use hydroxyzine as monotherapy for depression or as a substitute for evidence-based antidepressant treatment 6, 4